For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 180d
$45.58
Thesis
Novo Nordisk markets the semaglutide products Ozempic and Wegovy for type 2 diabetes and obesity. As a diversified company, its incretin franchise sits alongside a broader diabetes and metabolic portfolio.
Catalysts
- Semaglutide supply and manufacturing expansion
- Next-generation incretin clinical readouts
- Label expansions for Ozempic and Wegovy